Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices 4923 

Tissue Safety and Availability 

(ACBTSA) will hold a meeting. The 

meeting will be open to the public. 

DATES: The meeting will take place 

Tuesday April 7, 2105, from 8:00 a.m.– 

4:00 p.m. and Wednesday April 8, 2015, 

from 8:00 a.m.–3:30 p.m. 

ADDRESSES: NIH Conference Room, 5635 

Fishers Lane, Rockville, MD 20892. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James Berger, Designated Federal Officer 

for the ACBTSA, Senior Advisor for 

Blood and Tissue Policy, Office of the 

Assistant Secretary for Health, 

Department of Health and Human 

Services, 1101 Wootton Parkway, Suite 

250, Rockville, MD 20852. Phone: (240) 

453–8803; Fax (240) 453–8456; Email 

ACBTSA@hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

ACBTSA provides advice to the 

Secretary through the Assistant 

Secretary for Health. The Committee 

advises on a range of policy issues to 

include: (1) Identification of public 

health issues through surveillance of 

blood and tissue safety issues with 

national biovigilance data tools; (2) 

identification of public health issues 

that affect availability of blood, blood 

products, and tissues; (3) broad public 

health, ethical and legal issues related to 

the safety of blood, blood products, and 

tissues; (4) the impact of various 

economic factors (e.g., product cost and 

supply) on safety and availability of 

blood, blood products, and tissues; (5) 

risk communications related to blood 

transfusion and tissue transplantation; 

and (6) identification of infectious 

disease transmission issues for blood, 

organs, blood stem cells and tissues. 

The Committee has met regularly since 

its establishment in 1997. 

The ACBTSA has made previous 

recommendations on the need to 

improve tissue tracking and traceability. 

These recommendations focused on 

tracking adverse events, creating a 

unique identifier for each donor, and 

improving patient outcomes. Past 

recommendations made by the ACBTSA 

may be viewed at www.hhs.gov/

bloodsafety. 

The focus of the meeting will be to 

address current issues in tracking and 

traceability of tissue recovered from 

deceased donors. The discussion will 

focus on pertinent federal and state 

regulations, other mechanisms that 

impact tissue tracking and traceability, 

and current gaps in this area. Presenters 

will represent a wide range of 

government and non-government 

stakeholders, including federal agencies, 

accreditation organizations, tissue and 

eye banks, healthcare facilities, and 

medical practitioners. 

The public will have an opportunity 

to present their views to the Committee 

during a public comment session 

scheduled for April 8, 2015. Comments 

will be limited to five minutes per 

speaker and must be pertinent to the 

discussion. Pre-registration is required 

for participation in the public comment 

session. Any member of the public who 

would like to participate in this session 

is encouraged to contact the Designated 

Federal Officer at his/her earliest 

convenience to register for time (limited 

to 5 minutes) ; registration must be 

completed prior to close of business on 

April 1, 2015. If it is not possible to 

provide 30 copies of the material to be 

distributed at the meeting, then 

individuals are requested to provide a 

minimum of one (1) copy of the 

document(s) to be distributed prior to 

the close of business on April 1, 2015. 

It is also requested that any member of 

the public who wishes to provide 

comments to the Committee utilizing 

electronic data projection submit the 

necessary material to the Designated 

Federal Officer prior to the close of 

business on April 1, 2015. 

Dated: January 22, 2015. 

James J. Berger, 

Senior Advisor for Blood and Tissue Safety 

Policy. 

[FR Doc. 2015–01680 Filed 1–28–15; 8:45 am] 

BILLING CODE 4150–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Nominations to the Advisory 

Committee on Blood and Tissue Safety 

and Availability 

AGENCY: Office of the Secretary, Office 

of the Assistant Secretary for Health, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The Office of Assistant 

Secretary for Health (OASH) is seeking 

nominations of qualified individuals to 

be considered for appointment as 

members of the Advisory Committee on 

Blood and Tissue Safety and 

Availability (ACBTSA). ACBTSA is a 

Federal advisory committee within the 

Department of Health and Human 

Services. Management support for the 

activities of this Committee is the 

responsibility of the OASH. The 

qualified individuals will be nominated 

to the Secretary of Health and Human 

Services for consideration of 

appointment as members of the 

ACBTSA. Members of the Committee, 

including the Chair, are appointed by 

the Secretary. Members are invited to 

serve on the Committee for up to fouryear terms. 

DATES: All nominations must be 

received no later than 4:00 p.m. EDT on 

March 2, 2015, at the address listed 

below. 

ADDRESSES: All nominations should be 

mailed or delivered to Mr. James Berger, 

Senior Advisor for Blood and Tissue 

Policy; Office of Assistant Secretary for 

Health; Department of Health and 

Human Services; 1101 Wootton 

Parkway, Suite 250; Rockville, MD 

20852. Telephone: (240) 453–8803; Fax 

(240) 453–8456; Email ACBTSA@

hhs.gov. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James Berger, Senior Advisor for Blood 

and Tissue Policy. Contact information 

for Mr. Berger is provided above. 

A copy of the Committee charter and 

roster of the current membership can be 

obtained by contacting Mr. Berger or by 

accessing the ACBTSA Web site at 

http://www.hhs.gov/bloodsafety. http://

www.hhs.gov/bloodsafety. 

SUPPLEMENTARY INFORMATION: The 

ACBTSA shall provide advice to the 

Secretary through the Assistant 

Secretary for Health. The Committee 

shall advise on a range of policy issues 

to include: (1) Identification of public 

health issues through surveillance of 

blood and tissue safety issues with 

national biovigilance data tools; (2) 

identification of public health issues 

that affect availability of blood, blood 

products, and tissues; (3) broad public 

health, ethical and legal issues related to 

the safety of blood, blood products, and 

tissues; (4) the impact of various 

economic factors (e.g., product cost and 

supply) on safety and availability of 

blood, blood products, and tissues; (5) 

risk communications related to blood 

transfusion and tissue transplantation; 

and (6) identification of infectious 

disease transmission issues for blood, 

organs, blood stem cells and tissues. 

The Committee consists of 23 voting 

members. The Committee composition 

includes 14 public members, including 

the Chair, and nine (9) individuals 

designated to serve as official 

representative members. The public 

members are selected from state and 

local organizations, patient advocacy 

groups, provider organizations, 

academic researchers, ethicists, 

physicians, surgeons, scientists, risk 

communication experts, consumer 

advocates, and from among 

communities of persons who are 

frequent recipients of blood or blood 

products or who have received tissues 

or organs. The nine individuals who are 

appointed as official representatives are 

mstockstill on DSK4VPTVN1PROD with NOTICES

4924 Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices 

selected to serve the interests of the 

blood, blood products, tissue and organ 

professional organizations or business 

sectors. The representative members are 

selected from the following groups: The 

AABB (formerly the American 

Association of Blood Banks); American 

Association of Tissue Banks; Eye Bank 

Association of America; Association of 

Organ Procurement Organizations; and 

one of either the American National Red 

Cross or America’s Blood Centers on a 

rotating basis. The Committee 

composition can include additional 

representation from either the plasma 

protein fraction community or a trade 

organization; a manufacturer of blood, 

plasma, or other tissue/organ test kits; a 

manufacturer of blood, plasma or other 

tissue/organ equipment; a major 

hospital organization; or a major 

hospital accreditation organization. 

Where more than one company 

produces a specified product or process, 

representatives from those companies 

shall rotate on the same schedule as 

public members. 

All ACBTSA members are authorized 

to receive the prescribed per diem 

allowance and reimbursement for travel 

expenses that are incurred to attend 

meetings and conduct Committeerelated business, in accordance with 

Standard Government Travel 

Regulations. Individuals who are 

appointed to serve as public members 

are authorized also to receive a stipend 

for attending Committee meetings and 

to carry out other Committee-related 

business. Individuals who are appointed 

to serve as representative members for a 

particular interest group or industry are 

not authorized to receive a stipend for 

the performance of these duties. 

This announcement is to solicit 

nominations of qualified candidates to 

fill nine public member positions that 

are scheduled to be vacated on the 

ACBTSA. 

Nominations 

In accordance with the charter, 

persons nominated for appointment as 

members of the ACBTSA should be 

among authorities knowledgeable in 

blood banking, tissue banking, 

transfusion medicine, organ or tissue 

transplantation, plasma therapies, 

transfusion and transplantation safety, 

bioethics, and/or related disciplines. 

Nominations should be typewritten. The 

following information should be 

included in the package of material 

submitted for each individual being 

nominated for consideration of 

appointment: (a) The name, return 

address, daytime telephone number and 

affiliation(s) of the individual being 

nominated, the basis for the individual’s 

nomination, the category for which the 

individual is being nominated, and a 

statement bearing an original signature 

of the nominated individual that, if 

appointed, he or she is willing to serve 

as a member of the Committee; (b) the 

name, return address, and daytime 

telephone number at which the 

nominator may be contacted. 

Organizational nominators must 

identify a principal contact person in 

addition to the contact; and (c) a copy 

of a current curriculum vitae or resume 

for the nominated individual. 

Individuals can nominate themselves 

for consideration of appointment to the 

Committee. All nominations must 

include the required information. 

Incomplete nominations will not be 

processed for consideration. The letter 

from the nominator and certification of 

the nominated individual must bear 

original signatures; reproduced copies 

of these signatures are not acceptable. 

The Department is legally required to 

ensure that the membership of HHS 

Federal advisory committees is fairly 

balanced in terms of points of view 

represented and the functions to be 

performed by the advisory committee. 

Every effort is made to ensure that the 

views of women, all ethnic and racial 

groups, and people with disabilities are 

represented on HHS Federal Advisory 

committees and, therefore, the 

Department encourages nominations of 

qualified candidates from these groups. 

The Department also encourages 

geographic diversity in the composition 

of the committee. Appointment to this 

Committee shall be made without 

discrimination on the basis of age, race, 

ethnicity, gender, sexual orientation, 

disability, and cultural, religious, or 

socioeconomic status. 

The Standards of Ethical Conduct for 

Employees of the Executive Branch are 

applicable to individuals who are 

appointed as public members of Federal 

advisory committees. Individuals 

appointed to serve as public members of 

Federal advisory committees are 

classified as special government 

employees (SGEs). The federal conflict 

of interest laws are applicable to SGEs. 

Therefore, individuals appointed to 

serve as public members of the ACBTSA 

are subject to an ethics review. The 

ethics review is conducted to determine 

if the individual has any interests and/ 

or activities in the private sector that 

may conflict with performance of their 

official duties as a member of the 

Committee. Individuals appointed to 

serve as public members of the 

committee will be required to disclose 

information regarding financial 

holdings, consultancies, and research 

grants and/or contracts. 

Dated: January 22, 2015. 

James J. Berger, 

Senior Advisor for Blood and Tissue Policy. 

[FR Doc. 2015–01682 Filed 1–28–15; 8:45 am] 

BILLING CODE 4150–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30-Day–15–0931] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Written 

comments and/or suggestions regarding 

the items contained in this notice 

should be directed to the Attention: 

CDC Desk Officer, Office of Management 

and Budget, Washington, DC 20503 or 

by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

mstockstill on DSK4VPTVN1PROD with NOTICES